TORONTO, April 15, 2021 /CNW/ - HLS Therapeutics Inc.
("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical
company focused on central nervous system and cardiovascular
markets, announces that Gilbert
Godin, CEO, and Tim
Hendrickson, CFO, will participate in two upcoming investor
conferences: the Bloom Burton & Co. Healthcare Investor
Conference and the Stifel 2021 Canada Cross Sector Insight
Conference.
Bloom Burton & Co. Healthcare Investor Conference,
April 20-21, 2021:
- HLS will present Wednesday April 21,
2021 at 10:30a.m. ET
- Listen to the live webcast: click here
- Register for the virtual conference and request a one-on-one
investor meeting: click here
Stifel 2021 Canada Cross Sector Insight Conference,
April 21, 2021
- HLS will participate in one-on-one investor meetings on
April 21, 2021 at the Stifel 2021
Canada Cross Sector Insight Conference. To request a one-on-one
meeting, please contact your Stifel representative or click here to
register.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a
specialty pharmaceutical company focused on the acquisition and
commercialization of late-stage development, commercial stage
promoted and established branded pharmaceutical products in the
North American markets. HLS's focus is on products targeting the
central nervous system and cardiovascular therapeutic areas. HLS's
management team is composed of seasoned pharmaceutical executives
with a strong track record of success in these therapeutic areas
and at managing products in each of these lifecycle stages. For
more information, please visit: www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.